However, the largest Phase IIb trial involving 536 subjects failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading Metabolic Pharmaceuticals to terminate development in 2007
Franois-Xavier Maquart Researcher profile: ResearchGate Franois-Xavier Maquarts published work is relevant to the mechanistic foundation of GHK-Cu research, particularly collagen synthesis, fibroblast activity, extracellular matrix remodeling, and matrix metalloproteinase signaling
GHK is a naturally occurring peptide found in human plasma and other body fluids
One study conducted on mice found that epithalon reduced the size of lung metastases and decreased the development of mammary cancer in HEN/u2 subjects [4]
Oral: 100500 mcg, 12 times daily
You may report side effects to Health Canada at 1-866-234-2345